OTLCOTCPharmaceutical PreparationsUS GAAP · USD

Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing drug candidates for cancer, with an emphasis on RNA-based and antisense therapeutics. The company operates through Oncotelic and several subsidiaries, including Oncotelic, Inc., PointR Data, Pet2DAO, and EdgePoint AI.

Kysy yhtiöstä
Liikevoitto (EBIT)−3,2milj. USD
+10,9 %v/v
Nettotulos249milj. USD
+5 610,2 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−10,0−7,5−5,0−2,50,02,5milj. USD2020: 1,7 milj. USD2020: EBIT −7,6 milj. USD20202021: 1,7 milj. USD2021: EBIT −9,1 milj. USD20212022: EBIT −9,7 milj. USD20222023: 0,07 milj. USD2023: EBIT −6,6 milj. USD20232024: 0,07 milj. USD2024: EBIT −3,6 milj. USD20242025: EBIT −3,2 milj. USD2025−3,2
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Lead oncology candidate70 %

OT-101 and related cancer drug development programs.

RNA therapeutics platform20 %

Antisense and RNA-based therapeutic development capabilities.

Licensing and collaboration rights10 %

Out-licensing and joint venture arrangements for development assets.

Asiakkaat

The company’s direct customers are not traditional end-market buyers; its value is primarily realized through pharmaceutical licensing, development partnerships, and potential commercialization of approved therapies. In practice, the relevant counterparties are larger pharmaceutical companies, clinical development partners, and investors that fund drug development. The eventual end users of its products would be hospitals, oncologists, and patients if a candidate reaches approval.

Pharmaceutical licensing partners

Buy or license development rights to oncology assets such as OT-101.

Joint venture development partners

Co-fund and advance clinical programs in exchange for ownership or rights.

Capital providers

Provide equity or debt financing to support clinical-stage operations.

Future healthcare providers

Hospitals and physicians would use approved therapies in cancer care.

Strategia

The company’s strategy is to advance OT-101 and related oncology candidates through later-stage clinical trials and create value through either FDA approval or licensing to a larger pharmaceutical company. A major part of this strategy is using a joint venture structure to fund development while retaining an equity interest in the program. The broader platform also seeks to extend RNA/antisense applications beyond cancer into other diseases.

Advance OT-101 through clinical developmentKeskipitkä aikaväli

Clinical progress is the main driver of value creation in a pre-revenue biotech model.

Monetize through licensing or approvalKeskipitkä aikaväli

A larger partner or regulatory approval can convert scientific data into commercial value.

Use joint venture funding to reduce direct capital burdenLyhyt aikaväli

External funding supports development while limiting the company’s direct cash needs.

Maantiede

Oncotelic is headquartered in the United States and conducts its corporate and development activities through U.S. entities. Its lead program has been advanced through a joint venture structure that supports development work outside the company’s direct consolidated operations, including global licensing rights for OT-101. The business is therefore exposed to U.S. regulatory pathways as well as international development and commercialization channels.

Riskit

Oncotelic faces the standard risks of a clinical-stage biotech company: trial failure, regulatory setbacks, and uncertainty that any candidate will reach commercialization. The company also has concentrated exposure to a single lead program and relies on external funding structures, which increases execution and financing risk. Its reported going-concern uncertainty, debt obligations, and derivative-linked financing add further financial and dilution risk.

Järjestetty vakavuuden mukaan
Clinical development failureKriittinen

OT-101 and other candidates are still in development and may not succeed in later trials.

Kohdistuu: Lead oncology pipeline

Going-concern uncertaintyKriittinen

Limited cash resources and recurring losses raise doubt about continuity without new funding.

Kohdistuu: Corporate liquidity

Financing and dilution riskKorkea

The company has relied on debt and equity issuances to fund operations.

Kohdistuu: Capital structure

Regulatory approval riskKorkea

FDA approval requires positive clinical data and acceptable safety, which is not assured.

Kohdistuu: OT-101 and future oncology assets

Kirjanpito

Harkinnanvaraiset erät
Derivative accounting on debt

Changes in derivative fair value can create non-cash gains or losses in earnings.

Vaikutus: Can materially affect quarterly net loss

Impairment of long-lived and intangible assets

Clinical-stage assets may be written down if expected cash flows do not support carrying value.

Vaikutus: Can cause large non-cash charges

Stock-based compensation

Expense depends on grant-date valuation and estimated forfeitures.

Vaikutus: Affects operating expense and equity dilution

Equity-method investment in GMP Bio

The JV is not consolidated, so its economics are reflected differently than wholly owned operations.

Vaikutus: Changes comparability of R&D and operating costs

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Oragenics Inc

OGEN · Pharmaceutical Preparations

Ernexa Therapeutics Inc.

ERNAW · Pharmaceutical Preparations

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

IO Biotech, Inc.

IOBTQ · Pharmaceutical Preparations

Transcode Therapeutics, Inc.

RNAZ · Pharmaceutical Preparations

Päivitetty: 24.9.2026